IP Library › Granted Patent US 12,350,381
Granted Patent B2
US 12,350,381 · App. 17/296,200 · Granted Jul 8, 2025

Nanoparticles containing cellular membrane and uses thereof

Inventors: Weiwei Gao (San Diego, CA); Huiqing Zhu (San Diego, CA); Jian Guan (San Diego, CA); Yu-Wen Li (San Diego, CA)
Assignees: ARYTHA BIOSCIENCES, LLC; CELLICS THERAPEUTICS INC.
A61K9/5068A61K9/127A61K9/5015A61K9/5089
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,350,381
App. No.
17/296,200
Granted
Jul 8, 2025
Kind
B2
Abstract

The present disclosure relates to nanoparticles containing cellular membrane and uses thereof. The nanoparticle comprises an interior compartment (or an inner core) and an outer surface (or shell) comprising a cellular membrane derived from a cell, said interior compartment (or an inner core) not providing a solid support to said cellular membrane in said outer surface (or shell). The present disclosure also relates to processes of making the nanoparticles. The present disclosure further relates to compositions comprising the nanoparticles and methods of using the nanoparticles.

Claims (19)

1. A nanoparticle comprising an interior compartment and an outer surface comprising a cellular membrane isolated from a cell, said interior compartment not providing a solid support to said cellular membrane in said outer surface, and wherein:

a) said interior compartment comprises a liquid that is isotonic to a human cellular or physiological liquid; and

b) said outer surface comprises a steroid at a level from 40% (w/w) to 45% (w/w) and a sphingolipid at a level from 40% (w/w) to 50% (w/w), and from 10% (w/w) to 20% (w/w) said cellular membrane isolated from said cell, and

wherein said nanoparticle is prepared by an in vitro process.

2. The nanoparticle of claim 1 , wherein the interior compartment comprises a liquid that is isotonic to a human cellular liquid.

3. The nanoparticle of claim 1 , wherein the interior compartment comprises a liquid that is isotonic to a human physiological liquid.

4. The nanoparticle of claim 1 , wherein the cellular membrane comprises a plasma membrane.

5. The nanoparticle of claim 1 , wherein the steroid is a cholestane, a cholane, a pregnane, an androstane, or an estrane, or the steroid is selected from the group consisting of a gonane, testosterone, cholic acid, dexamethasone, lanosterol, progesterone, medrogestone, β-sitosterol, cholesterol, and 5α-cholestane.

6. The nanoparticle of claim 1 , wherein the outer surface comprises 40% (w/w) of the steroid.

7. The nanoparticle of claim 1 , wherein the outer surface comprises 45% (w/w) of the steroid.

8. The nanoparticle of claim 1 , wherein the interior compartment has a pH ranging from about 4 to about 10.

9. The nanoparticle of claim 1 , which further comprises a releasable cargo.

10. The nanoparticle of claim 1 , wherein the nanoparticle lacks cytoplasmic constituents of the cell from which the cellular membrane is isolated.

11. The nanoparticle of claim 1 , wherein the interior compartment comprises a salt, a sugar or a sugar alcohol.

12. The nanoparticle of claim 1 , wherein the interior compartment comprises a sugar or a sugar alcohol, and the outer surface comprises a plasma membrane isolated from a red blood cell.

13. The nanoparticle of claim 1 , wherein the outer surface comprises the sphingolipid at a level of 45% (w/w).

14. The nanoparticle of claim 1 , wherein the steroid is cholesterol.

15. The nanoparticle of claim 1 , wherein the sphingolipid is sphingomyelin.

16. An immunogenic composition, which comprises an effective amount of a nanoparticle of claim 1 .

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 1, 2024
From: GAO, WEIWEI
To: ARYTHA BIOSCIENCES LLC
Reel/Frame 067883/0692 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 1, 2024
From: ZHU, HUIQING; GUAN, JIAN; LI, YU-WEN
To: CELLICS THERAPEUTICS INC.
Reel/Frame 067883/0829 →
Continuity (2)
Provisional Application 62771561 · Nov 26, 2018
Related Publication 20220362162A1 · Nov 17, 2022
References Cited (71)
US 4321259A · Nicolau et al. · 1982 [cited by applicant]
US 11359058B2 · Gao et al. · 2022 [cited by applicant]
US 20080317767A1 · Braxmeier et al. · 2008 [cited by applicant]
US 20130295159A1 · Kester et al. · 2013 [cited by applicant]
US 20130337066A1 · Zhang et al. · 2013 [cited by applicant]
US 20170360706A1 · Ghoroghchian · 2017 [cited by applicant]
CN 103857387A · 2014 [cited by applicant]
CN 108699253A · 2018 [cited by applicant]
CN 114206360A · 2022 [cited by applicant]
JP 59157033A · 1984 [cited by applicant]
JP 2007238568A · 2007 [cited by applicant]
JP 5726620A · 2015 [cited by applicant]
JP 7518830B2 · 2024 [cited by applicant]
JP 2024133629A · 2024 [cited by applicant]
WO 2016090111A1 · 2016 [cited by applicant]
WO 2016144376A1 · 2016 [cited by applicant]
WO WO2019022671A1 · 2019 [cited by examiner]
Dodge, James T., Carolyn Mitchell, and Donald J. Hanahan. “The preparation and chemical characteristics of hemoglobin-free ghosts of human erythrocytes.” Archives of biochemistry and biophysics 100.1 (1963): 119-130. (Y… [cited by examiner]
Hoffman, Joseph F. “Biconcave shape of human red-blood-cell ghosts relies on density differences between the rim and dimple of the ghost's plasma membrane.” Proceedings of the National Academy of Sciences 113.51 (2016):… [cited by examiner]
Chakrabarti, Rima S., et al. “Variability of cholesterol accessibility in human red blood cells measured using a bacterial cholesterol-binding toxin.” eLife 6 (2017): e23355. (Year: 2017). [cited by examiner]
Zhang, Xinxin, et al. “Remote loading of small-molecule therapeutics into cholesterol-enriched cell-membrane-derived vesicles.” Angewandte Chemie International Edition 56.45 (Oct. 5, 2017): 14075-14079 and S1-S5. (Year:… [cited by examiner]
Li, Cunbo, et al. “Protection of the biconcave profile of human erythrocytes against osmotic damage by ultraviolet-A irradiation through membrane-cytoskeleton enhancement.” Cell Death Discovery 3.1 (2017): 1-10. (Year: … [cited by examiner]
Bogdanova A, Kaestner L, Simionato G, Wickrema A and Makhro A (2020) Heterogeneity of Red Blood Cells: Causes and Consequences. Front. Physiol. 11:392. doi: 10.3389/fphys.2020.00392 (Year: 2020). [cited by examiner]
Written Opinion of the International Searching Authority for International Application No. PCT/US2019/063110, mailed Feb. 21, 2020 (11 pages). [cited by applicant]
PCT International Search Report for International Application No. PCT/US2019/063110, mailed Feb. 21, 2020 (3 pages). [cited by applicant]
PCT International Preliminary Report on Patentability for International Application No. PCT/US2019/063110, issued May 25, 2021 (12 pages). [cited by applicant]
Communication to Rule 161(2) and 162 EPC for European Patent Application 19 889 860.3, dated Jul. 9, 2021 (3 pages). [cited by applicant]
Response to Communication to Rule 161(2) and 162 EPC for European Patent Application 19 889 860.3, dated Jan. 18, 2022 (3 pages). [cited by applicant]
Marked-Up Claims for European Patent Application 19 889 860.3, dated Jan. 18, 2022 (34 pages). [cited by applicant]
Bonarska-Kujawa, et al. “Interaction of Selected Anthocyanins with Erythrocytes and Liposome Membranes”. Cellular & Molecular Biology Letters, vol. 17: 289-308 (2012). [cited by applicant]
Enomoto, et al. “Asymmetric Binding of Cytochrome b5 to the Membrane of Human Erythrocyte Ghosts”. Biochimica et Biophysica Acta, vol. 466: 136-147 (1977). [cited by applicant]
Shiga, et al. “Erythrocyte Rheology”. Critical Reviews in Oncology/Hematology, vol. 10(1): 9-48 (1990). [cited by applicant]
Zhang, et al. “Remote Loading of Small-Molecule Therapeutics into Cholesterol-Enriched Cell-Membrane-Derived Vesicles”. Angew. Chem. Int. Ed., vol. 56: 14075-14079 (2017). [cited by applicant]
Extended European Search Report from European Patent Application 19 889 860.3, dated Sep. 8, 2022 (10 pages). [cited by applicant]
Response to Communication Pursuant to Rules 70(2) and 70a(2) EPC from European Patent Application 19 889 860.3, dated Apr. 4, 2023 (14 pages). [cited by applicant]
Marked-Up Claims from European Patent Application 19 889 860.3, dated Apr. 4, 2023 (5 pages). [cited by applicant]
Communication Pursuant to Rules 70(2) and 70a(2) EPC from European Patent Application 19 889 860.3, dated Sep. 27, 2022 (1 page). [cited by applicant]
Amended Claims from Japanese Patent Application No. 2021-529714, filed Nov. 24, 2022 (24 pages). [cited by applicant]
Request for Examination from Japanese Patent Application No. 2021-529714, filed Nov. 24, 2022 (1 page). [cited by applicant]
Voluntary Amendment from Japanese Patent Application No. 2021-529714, filed Nov. 24, 2022 (23 pages). [cited by applicant]
Petition from Japanese Patent Application No. 2021-529714, filed Nov. 24, 2022 (2 pages). [cited by applicant]
English Version of the Amended Claims from Brazilian Application No. BR112021010125-0, dated Oct. 25, 2022 (4 pages). [cited by applicant]
Request for Examination and Voluntary Amendment as filed for Brazilian Application No. BR112021010125-0, dated Oct. 25, 2022 (116 pages). [cited by applicant]
Examination Request dated Oct. 19, 2023, AU App. No. 2019388869. [cited by applicant]
Postponement of Acceptance for Patent Application dated Oct. 19, 2023, AU App. No. 2019388869. [cited by applicant]
Office action dated Jul. 4, 2023, CN App. No. 201980089873.5. [cited by applicant]
Office action dated Aug. 31, 2023, JP App. No. 2021-529714. [cited by applicant]
Zhang, et al; “Remote Loading of Small-Molecule Therapeutics into Cholesterol-Enriched Cell-Membrane-Derived Vesicles”; Angew. Chem. Int. ED., 2017, vol. 56, pp. 14075-14079. [cited by applicant]
Acknowledgment Request for Examination dated Feb. 10, 2023, CA App. No. 3,120,860. [cited by applicant]
Response as Filed on Nov. 17, 2023 for the First Office Action, CN Application No. 201980089873.5. [cited by applicant]
Claims as Filed on Nov. 17, 2023, CN Application No. 201980089873.5. [cited by applicant]
Amended Claims as Filed on Dec. 5, 2023 for Japanese Patent Application No. 2021-529714. [cited by applicant]
Response as filed on Dec. 5, 2023, for Japanese Patent Application No. 2021-529714. [cited by applicant]
Amendment as filed on Dec. 5, 2023, for Japanese Patent Application No. 2021-529714. [cited by applicant]
CN Application No. 201980089873.5, Third office action dated Jul. 23, 2024. [cited by applicant]
Examiner's Report dated Jan. 16, 2024, Canadian Patent Application No. 3,120,860 [cited by applicant]
Response to Exam Report dated May 15, 2024, Canadian Patent Application No. 3,120,860. [cited by applicant]
Second Office action dated Apr. 19, 2024, Chinese Application No. 201980089873.5. [cited by applicant]
Response to Second Office action dated Jun. 17, 2024, Chinese Application No. 201980089873.5. [cited by applicant]
Third Office action dated Jul. 23, 2024, Chinese Application No. 201980089873.5. [cited by applicant]
Official Action dated Feb. 14, 2024, Japanese Patent Application No. 2021-529714. [cited by applicant]
Amendment dated May 17, 2024, Japanese Patent Application No. 2021-529714. [cited by applicant]
Argument dated May 17, 2024, Japanese Patent Application No. 2021-529714. [cited by applicant]
Amended claims dated May 17, 2024, Japanese Patent Application No. 2021-529714. [cited by applicant]
Allowed claims dated Jun. 5, 2024, Japanese Patent Application No. 2021-529714. [cited by applicant]
Notice of Allowance dated Jun. 5, 2024, Japanese Patent Application No. 2021-529714. [cited by applicant]
CN Application No. 201980089873.5; English translation of the third Office Action. [cited by applicant]
CN Application No. 201980089873.5; Response to the third Office Action. [cited by applicant]
CN Application No. 201980089873.5; amended claims filed with the Response to the third Office Action. [cited by applicant]
CN Application No. 201980089873.5; Notification of Going Through the Formalities of Registration. [cited by applicant]
CN Application No. 201980089873.5; Notification of Granting Invention Patent Right issued by the CNIPA. [cited by applicant]